TCT 216: Outcomes based on the completeness of revascularization in patients with three-vessel coronary artery disease: The FAME 3 Trial 

<p>Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: </p><ul><li>Grant Support/Research Contract - Abbott; Boston Scientific Corporation; Medtronic; Terumo Medical Corporation</li></ul>